<DOC>
	<DOCNO>NCT01411410</DOCNO>
	<brief_summary>This open label Phase 1 study involve treat subject advanced cancer BAY80-6946 combination paclitaxel . It determine maximum tolerate dose ( MTD ) recommend Phase 2 dose ( RP2D ) BAY80-6946 combination paclitaxel . The trial involve multiple participate site US . Following determination MTD , expansion cohort 20 evaluable subject breast cancer plan . Finally , 16 patient enrol treatment ( Cohort 3 ) . A new expansion cohort modify dose cohort introduce ( Cohort 4 : breast cancer expansion cohort modify dose ) another 20 subject plan enrol treatment .</brief_summary>
	<brief_title>Phase I Study PI3 ( Phosphoinositol 3 ) -Kinase Inhibitor BAY80-6946 With Paclitaxel Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Subjects must define tumor classification ( ie , TNBC , HER2+ Luminal ) enrollment . If tumor classification available subject enrol . Tumor classification base analysis archive tumor tissue , analysis tumor tissue collect time proximal screening . Subject profile also derive analysis fresh tumor tissue obtain screen . Shipment specimen ( archival fresh tumor tissue , blood , plasma ) central lab take place subject enrollment . No prior paclitaxel treatment subject dose escalation phase . MTD cohort expansion subject may prior paclitaxel , must experience moderate severe hypersensitivity reaction drug . Peripheral neuropathy must Grade ≤ 1 . Histological cytological documentation nonhematologic malignant solid tumor , exclude primary brain spinal tumor . Patients prior central nervous system metastasis eligible follow apply : Definitive treatment lesion ( eg , surgery , radiation ) complete least three month prior enrollment All lesion must stable improve MRI scan perform within one month enrollment All symptoms prior CNS metastases stable . At least one measurable lesion evaluable disease , per RECIST 1.1 ECOG Performance Status Assessment 0 1 Life expectancy least 12 week History moderate severe hypersensitivity ( allergy ) drug formulate Cremophor® EL ( polyoxyethylated castor oil ) , vitamin K , cyclosporin injection concentrate teniposide injection concentrate Preexisting interstitial lung disease and/or severe impaired pulmonary function History cardiac disease ; congestive heart failure ( CHF ) &gt; NYHA Class II ; active coronary artery disease , myocardial infarction within 6 month prior study entry ; new onset angina within 3 month prior study entry unstable angina , ventricular cardiac arrhythmia require antiarrhythmic therapy Prior diagnosis Type 1 2 diabetes mellitus , hyperglycemia ( define consistent fast blood plasma glucose &gt; 125 mg/dL ) HgBA1c ≥ 7 % Active clinically serious infection Grade ≥ 2 ( NCICTCAE version 4.0 ) , include viral hepatitis Poorly control seizure disorder Poorly control hypertension , define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management Known human immunodeficiency virus ( HIV ) infection chronic hepatitis C B Subjects undergoing renal dialysis Known bleed diathesis Pregnant breast feed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>phase I</keyword>
	<keyword>phosphatidylinositol 3΄-kinase ( PI3K )</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>Maximum tolerate Dose</keyword>
</DOC>